The Valley Desk

Publications on Clinical care from Johnson & Johnson

A filtered view. Show the full list.

Refine

428 publications · listings 1–24

Listings

  1. Clinical trial reportArthritis & rheumatology (Hoboken, N.J.)

    Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study

    Verified Author affiliations on the Europe PMC record name Drexel University College of Medicine, Johnson & Johnson, Perelman School of Medicine, University of Pennsylvania, with Drexel University linked by the institution reference. Affiliation source

    Clinical careAdded

  2. Clinical trial reportArthritis & rheumatology (Hoboken, N.J.)

    Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept Study

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  3. ArticleBritish journal of clinical pharmacology

    Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  4. Clinical trial reportClinical pharmacology in drug development

    A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single-Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  5. Clinical trial reportClinical pharmacology in drug development

    A Phase 1, Open-Label, Single-Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  6. ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

    A scalable workflow using digital cognitive assessment and pTau217 for MCI detection

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  7. Clinical trial reportJournal of clinical pharmacology

    Nipocalimab Phase 3 Dose Selection for Severe Hemolytic Disease of the Fetus and Newborn

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  8. ArticleEJHaem

    Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2-Year Follow-Up From MajesTEC-1 China Cohort

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  9. ArticleJournal of pediatric gastroenterology and nutrition

    Effectiveness and safety of ustekinumab in pediatric Crohn's disease: Results of the REALITI study

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  10. ArticleCPT: pharmacometrics & systems pharmacology

    Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  11. ArticlePulmonary circulation

    Time to Therapy Activation and Initial Combination Therapy (TITANIC) for Patients With Pulmonary Arterial Hypertension

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  12. ArticlePulmonary circulation

    Use of Machine-Learning Models to Identify Clinical Features Associated With A Future Clinical Worsening Event in Patients With Pulmonary Arterial Hypertension

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  13. Clinical trial reportCancer immunology, immunotherapy : CII

    A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  14. Clinical trial reportCancer immunology, immunotherapy : CII

    A phase 1 study of VAC85135, a neoantigen vaccine regimen targeting calreticulin and JAK2 mutations, in combination with ipilimumab in patients with myeloproliferative neoplasms

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  15. Clinical trial reportCancer chemotherapy and pharmacology

    A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer

    Verified Author affiliations on the Europe PMC record name Johnson & Johnson, Thomas Jefferson University Hospital, with Jefferson Health linked by the institution reference. Affiliation source

    Clinical careAdded

  16. Clinical trial reportJournal of neurology

    Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  17. Clinical trial reportJournal of neurology

    Health-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  18. ArticleTargeted oncology

    Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine Dynamics

    Verified Author affiliations on the Europe PMC record name Johnson & Johnson, Perelman School of Medicine, University of Pennsylvania. Affiliation source

    Clinical careAdded

  19. ReviewAdvances in therapy

    Transitioning Prostacyclin Pathway Agents to Oral Selexipag in Patients with Pulmonary Arterial Hypertension: A Systematic Literature Review

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  20. ArticleAdvances in therapy

    Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  21. ArticleAdvances in therapy

    FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  22. ArticleAdvances in therapy

    Real-World PSA Response and Overall Survival Among Men with mCSPC Receiving Apalutamide Versus Darolutamide (Both Without Docetaxel) in the US

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  23. ArticleAdvances in therapy

    BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  24. ReviewAdvances in therapy

    Golimumab for the Treatment of Axial Spondyloarthritis: Integrating Clinical Outcomes with Real-World Patient Benefits

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded